Skip to content
Checked.be
Complete company report
Generated 14-08-2026
Active BE 0416.405.162Private limited company

SOBEN Pharma Robeerst

Rue de Bruxelles 17 ·4130 Esneux, Belgium· 49 yrs active
Sector: Detailhandel in farmaceutische producten (47730)
Conclusion Checked

The computed 12-month bankruptcy probability of SOBEN Pharma Robeerst is 0.6% (low). The 2025 annual accounts show equity of €22k and a net result of €-95k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 39% of 242 sector peers (fiscal year 2025). The company has been active since 1976 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 8 annual accounts.
Key figures
Equity €22k
Net result €-95k
Staff (FTE) 0.7
Better than sector 39%
Snowflake analysis 5 of 5 axes measured · computed by Checked
Health7Profitability0Solvency14Growth32Stability100
31 / 100

Fragile profile, watch profitability in particular.

All 5 axes are computed from data Checked has read.

Health 7
Profitability 0
Solvency 14
Growth 32
Stability 100
Bankruptcy probability (12 mo) Checked model v1 · free
0.6% Low
0%0,5%1,5%4%10%≥25%
Long track record −Higher-failure-rate sector +Annual accounts: weaker financial profile +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Risk Assessment rule-based
0 / 100
Low risk
Trust signals 2 signals
Long-established
Founded in 1976, 49 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags 0 events
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Health barometer FY 2025 · computed
7 / 100 Critical
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview10 NBB filings
Annual accounts filed on 04-05-2026 with the NBB · fiscal year 2025 · volledig
€-100k€0€100k€200kOperating result 2021: €155k€155kNet result 2021: €121k€121kOperating result 2022: €142k€142kNet result 2022: €116k€116kOperating result 2023: €-4k€-4kNet result 2023: €-23k€-23kOperating result 2024: €59k€59kNet result 2024: €28k€28kOperating result 2025: €-99k€-99kNet result 2025: €-95k€-95k20212022202320242025
Operating resultNet result
Sector comparison
Fiscal year 2025 · NACE 47, Retail trade · compared within the same schema type (full schema)
Metric This company Sector median Position in the sector
Solvency 7.9% 13.8%
better than 39% of 242 sector peers
Net result €-95k €19k
better than 16% of 242 sector peers
Equity €22k €94k
better than 30% of 242 sector peers
Gross operating margin €-44k €319k
better than 5% of 214 sector peers
Staff costs €28k €279k
higher than 7% of 214 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
EBITDA
€-73k
- 18-25
Net profit
€-95k
- 18-25
Cash flow
€-69k
- 18-25
Total assets
€283k
-67.6% 18-25
Equity
€22k
-81.0% 18-25
Working capital
€-3k
+98.6% 18-25
Employees (FTE)
1
-46.2% 18-25
Staff costs
€28k
-71.8% 18-25
Income taxes
€-3
- 18-25
Dividends
€0
-100.0% 18-25
Debt
€261k
-64.4% 18-25
Debt ≤ 1y
€35k
-92.4% 18-25
Debt > 1y
€226k
-17.0% 18-25
Current ratio
0.90
+86.4% 18-25
Quick ratio
0.90
+220.4% 18-25
Solvency
7.9%
-41.4% 18-25
Debt / equity
11.72
+87.8% 18-25
ROE
-427.2%
- 18-25
ROA
-33.6%
- 18-25
Interest coverage
-2.48
- 18-25
Figures by fiscal year
Fiscal year2025
Depositvolledig
Revenue-
EBITDA€-73k
Net profit€-95k
Cash flow€-69k
Staff costs€28k
Income taxes€-3
Dividends€0
Total assets€283k
Equity€22k
Debt€261k
of which ≤ 1y€35k
of which > 1y€226k
Working capital€-3k
Employees (FTE)0.7
Ratios (computed)
2025
Current ratio0.90
Quick ratio0.90
Working capital ratio-1.2%
Solvency7.9%
Debt / equity11.72
Long-term debt ratio10.14
Interest coverage-2.48
Gross margin-
Net margin-
ROA-33.6%
ROE-427.2%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€283k
Fixed assets 21/28€251k
Tangible fixed assets 22/27€159k
Financial fixed assets 28€93k
Current assets 29/58€32k
Stocks & contracts in progress 3€0
Amounts receivable within one year 40/41€27k
Cash & bank 54/58€4k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€283k
Equity 10/15€22k
Contributions / capital 10/11€19k
Reserves 13€3k
Accumulated profits (losses) 14€0
Provisions & deferred taxes 16€0
Amounts payable 17/49€261k
Amounts payable after one year 17€226k
Amounts payable within one year 42/48€35k
Trade debts payable within one year 44€1k
Income statement
Gross operating margin 9900€-44k
Operating result 9901€-99k
Financial income 75€8k
Financial charges 65€29k
Result before taxes 9903€-120k
Income taxes 67/77€-3
Net result for the period 9904€-95k
Result to be appropriated 9905€-20k
You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.
Legal Structure
NACE primary Detailhandel in farmaceutische producten(47730)
Legal form Private limited company(610)
Incorporation20-09-1976
StatusActive
Postal code4130
Establishment units 1 location
SOBEN Pharma Robeerst
Rue de Bruxelles 17, 4130 EsneuxBemiddelingsactiviteiten in verband met goederenvervoer
since 19762.012.721.591
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Real-estate footprint Source: CBE × cadastre

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
62032E0524/00R002 Wallonia 255 m² 1 · 85 m² 12.8 m · 4 fl.
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates 11 events

A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.

2026
04-05-2026
NBB filing Annual accounts filed
fiscal year 2025 · volledig
2025
05-05-2025
NBB filing Annual accounts filed
fiscal year 2024 · volledig
2024
10-05-2024
NBB filing Annual accounts filed
fiscal year 2023 · volledig
2023
22-05-2023
NBB filing Annual accounts filed
fiscal year 2022 · volledig
22-05-2023
State Gazette act Capital & shares
Aurélie LEONARD
2022
23-06-2022
NBB filing Annual accounts filed
fiscal year 2021 · volledig
2021
03-05-2021
NBB filing Annual accounts filed
fiscal year 2020 · volledig
2020
19-05-2020
NBB filing Annual accounts filed
fiscal year 2019 · volledig
2019
06-05-2019
NBB filing Annual accounts filed
fiscal year 2018 · volledig
2018
07-05-2018
NBB filing Annual accounts filed
fiscal year 2017 · volledig
2017
12-05-2017
NBB filing Annual accounts filed
fiscal year 2016 · volledig
Belgisch Staatsblad, acts 1 acts
Capital history · 1
22-05-2023
Capital change
All acts · 1 updated 3 years ago
2023
22-05-2023 Restructuring of share classes Capital & shares·Aurélie LEONARD
Notary: Aurélie LEONARD · Liège
Technical details 
{
  "events": [
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Aur\u00E9lie LEONARD",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Li\u00E8ge",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2023-05-22",
    "filing_date": "2023-05-18",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2023-05-15",
    "unanimous": true,
    "under_authorized_capital": true,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": true,
    "firm_kbo": null,
    "firm_name": null,
    "ibr_number": null,
    "mission_type": null,
    "individual_name": null
  },
  "subject_company": {
    "kbo": "0416.405.162",
    "name_full": "PHARMACIE ROBEERST",
    "legal_form": "SRL",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Aur\u00E9lie LEONARD",
    "org_rep_person_name": null,
    "person_role_at_subject": "notaire"
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal d\u0027assembl\u00E9e",
    "coordination des statuts"
  ],
  "shareholders_after": [],
  "share_classes_after": []
}
Credit advice verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.
AI due-diligence brief Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works
Company registry (CBE) Crossroads Bank
Activities
Apotheken47730Detailhandel in farmaceutische producten47730Apothekers52310
Primary activity highlighted.
Names & trade names
Legal nameFR SOBEN Pharma Robeerst
Registered office
Rue de Bruxelles 17
4130 Esneux, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies Comparable size · 496 of 5,225 companies in this sector with filed accounts
AGEPHAR BE 1002.549.933 · Marche-en-Famenne
EL MANAGEMENT BE 1003.039.287 · Waremme
OKINEO System BE 0761.565.905 · Colfontaine
APOTHEEK PALEIS BE 0756.885.456 · Antwerpen
PHARMACIE SAINTE-WALBURGE BE 0871.780.471 · Soumagne
Source: Belgian State Gazette, CBE, NBB · generated via checked.be · indicative